Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Casanova MJ
- Rubín de Célix C
- Riestra S
- Lucendo AJ
- Benítez JM
- Navarro-Llavat M
- Barrio J
- Morales-Alvarado VJ
- Rivero M
- Busquets D
- Leo-Carnerero E
- Nantes-Castillejo O
- Navarro P
- Van Domselaar M
- Gutiérrez-Casbas A
- Alonso-Abreu I
- Barreiro-de Acosta M
- Fernández-Salazar L
- Martín-Arranz MD
- García-Morales N
- Guardiola J
- Bouhmidi-Assakali A
- Esteve M
- Muñoz-Villafranca C
- Rodríguez-Lago I
- Ceballos D
- Guerra I
- Mañosa M
- Marín-Jiménez I
- Vera-Mendoza I
- Garre A
- Chaparro M
- Gisbert JP
- EXIT long-term study group of GETECCU
Grupos
Abstract
BACKGROUND: The EXIT trial found no difference in sustained remission at 12 months between inflammatory bowel disease (IBD) patients in remission who withdrew anti-TNF therapy [withdrawal arm (WA)] and those who maintained treatment [maintenance arm (MA)]. AIMS: To compare the long-term risk of relapse between these groups and assess the response to anti-TNF resumption. METHODS: This was a follow-up extension of the EXIT trial. We analysed long-term outcomes of patients in sustained clinical remission from the start of EXIT. RESULTS: We included 125 patients (63 in MA and 62 in WA). Median follow-up was 12 months for MA and 26 months for WA. The cumulative incidence of relapse (95% CI) was 35% (23%-48%) in MA and 47% (34%-60%) in WA; p = 0.3. In MA, relapses occurred in 8% of patients by 12 months and 47% by 24 months. In WA, relapses occurred in 16% by 12 months and 39% by 24 months. The incidence rate of relapse per patient-year was 22% in MA and 19% in WA. Baseline faecal calprotectin > 250 µg/g was the only variable associated with a higher risk of relapse. Of the 29 patients who relapsed in WA, 26 (90%) resumed anti-TNF therapy; of these, 69% regained clinical remission. CONCLUSION: In this extended analysis of patients included in the EXIT trial, withdrawing anti-TNF therapy in patients with IBD in remission was not associated with a higher long-term relapse risk.
© 2025 John Wiley & Sons Ltd.
Datos de la publicación
- ISSN/ISSNe:
- 0269-2813, 1365-2036
- Tipo:
- Article
- Páginas:
- 59-71
- DOI:
- 10.1111/apt.70172
- PubMed:
- 40317957
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 2,850 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
ALIMENTARY PHARMACOLOGY & THERAPEUTICS WILEY
Citas Recibidas en Web of Science: 5
Documentos
- No hay documentos
Filiaciones
Keywords
- Crohn's disease; anti-TNF; inflammatory bowel disease; maintenance; ulcerative colitis
Cita
Casanova MJ,Rubín de Célix C,Riestra S,Lucendo AJ,Benítez JM,Navarro M,Barrio J,Morales VJ,Rivero M,Busquets D,Leo E,Nantes O,Navarro P,Van M,Gutiérrez A,Alonso I,Barreiro M,Fernández L,IBORRA M,Martín MD,García N,Guardiola J,Bouhmidi A,Esteve M,Muñoz C,Rodríguez I,Ceballos D,Guerra I,Mañosa M,Marín I,Vera I,Garre A,Chaparro M,Gisbert JP,EXIT long G. Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCU. Aliment. Pharmacol. Ther. 2025. 62. (1):p. 59-71. IF:6,800. (1).
Portal de investigación